Treatment with Tiotropium plus Olodaterol Respimat improves physical functioning of COPD patients in a real life setting

Objective: The free combination of inhaled tiotropium and olodaterol has been shown to improve lung function and quality of life in patients with chronic obstructive pulmonary disease (COPD). Here, we seek to investigate the effectiveness of this free combination in terms of physical functioning within an observational study. Methods: Patients with COPD (GOLD stage II-IV/B-D) were initially treated with or switched to tiotropium (via HandiHaler®/Respimat®) and olodaterol (Respimat®) once daily for 4 to 6 weeks in a prospective, open-label observational study in 800 office-based pulmonology and general care pract…